Filing summary
Entity note: The supplied filing is PharmAthene, Inc.’s Form 10-Q for the quarter ended June 30, 2015, not an Altimmune, Inc. filing. The summary below reflects the filing text provided.
Business context and reporting period
PharmAthene develops biodefense countermeasures, including anthrax vaccines. The filing reports second-quarter and six-month results through June 30, 2015, compared with the corresponding 2014 periods. In March 2015, the company approved a realignment plan that eliminated about two-thirds of its workforce, prioritizing its NIAID contract, potential partnerships for its biodefense assets, and the SIGA litigation.
Key financial metrics
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $1.15 million | $3.66 million | $8.22 million | $7.40 million |
| Operating expenses | $3.11 million | $4.83 million | $9.02 million | $10.97 million |
| Operating loss | $1.96 million | $1.17 million | $0.80 million | $3.57 million |
| Net loss | $2.34 million | $0.44 million | $0.88 million | $2.70 million |
| Net loss per share | $0.04 | $0.01 | $0.01 | $0.05 |
At June 30, 2015, cash and cash equivalents were $18.4 million, total current assets $19.9 million, current liabilities $3.3 million, and total liabilities $4.3 million. Cash declined by $0.23 million from year-end 2014. For the first half, operating cash use was $0.06 million, investing cash use $0.05 million, and financing cash use $0.12 million. The company had approximately $0.3 million remaining on its GE Capital term loan, due at maturity in September 2015; approximately $0.5 million was available on the revolver, with none drawn. No gross-margin figure is presented.
Material changes versus prior periods
- Q2 revenue fell 70% year over year, mainly because BARDA had de-scoped the SparVax contract and that contract formally expired in February 2015; the prior-year quarter also included rBChE bioscavenger revenue.
- First-half revenue increased 11%, principally reflecting a one-time $5.8 million BARDA audit-related recovery recognized in Q1 and collected in April. NIAID contract revenue also contributed; the rBChE contract had ended in September 2014.
- Research and development expense fell 50% in Q2 and 52% for the first half, while general and administrative expense fell 25% and 21%, respectively, reflecting reduced program activity and workforce reductions.
- First-half 2015 included $2.1 million of restructuring expense, primarily severance. The company recorded a $0.23 million foreign-currency translation loss in Q2 upon substantially liquidating its UK subsidiary.
- Q2 net loss widened despite lower operating expenses, in part because other expense replaced the prior-year other income, including the effect of derivative fair-value changes and the translation adjustment.
Outlook, risks, contingencies, and unusual items
- Management said cash on hand at June 30 was expected to fund operations through at least the end of 2016, based on expected 2015 operating needs and capital expenditures. The company nevertheless expected future losses and warned that insufficient funding could require it to cease operations.
- The NIAID contract had approximately $5.2 million of initial base-period funding and a potential value of up to $28.1 million if technical milestones are met and all options are exercised. Options are at NIAID’s discretion; without options, the contract would expire January 5, 2016. Management expected Q3 and Q4 general and administrative expense to be consistent with Q2.
- A Delaware court judgment awarded PharmAthene $194.6 million against SIGA, plus post-judgment interest. SIGA appealed, is in Chapter 11 bankruptcy, and has stated it lacks sufficient cash to pay the award. The appeal, bankruptcy proceedings, and collectability remain uncertain; PharmAthene recorded no receivable or litigation proceeds.
- Management said further government funding for liquid SparVax, Valortim, and rBChE was unlikely. The SparVax contract audit for 2014 costs remained pending, and any additional recovery and its timing were uncertain.
- GE Capital could assert a default related to BARDA’s SparVax contract de-scope and potentially accelerate obligations, although the company said it had received no default notice. Additional equity financing could dilute shareholders; $3.0 million remained available under the controlled equity offering, but the company reported no 2015 sales under it and no current plans to sell shares.
- On July 6, 2015, after quarter-end, PharmAthene signed a license agreement with Immunovaccine for its DepoVax platform. Terms include annual payments of $200,000, milestone and sales-target payments, and royalties.
Important facts for investors to verify
- Confirm the issuer: the supplied 10-Q is for PharmAthene, not Altimmune.
- Check subsequent developments in SIGA’s appeal, bankruptcy, and the prospects and timing of any recovery on the $194.6 million judgment.
- Verify NIAID funding, milestone progress, and whether contract options are exercised, alongside the status of BARDA’s 2014 cost audit.
- Track cash use, restructuring payments, the September 2015 GE Capital maturity, and any need for additional or dilutive financing.
- Review the Immunovaccine license’s payment obligations and development, regulatory, and commercial milestones.